Tenelia (teneligliptin) / Mitsubishi Tanabe, Handok - LARVOL DELTA

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. (PubMed, Pharmacoepidemiol Drug Saf) - "DPP-4 inhibitors remain effective and well-tolerated options for managing T2DM."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials. (PubMed, J Diabetes Complications) - "Current randomized evidence indicates class-level neutrality of DPP-4 inhibitors on DR incidence, with no dose-response signal. Choice among gliptins may therefore be guided primarily by glycemic efficacy, safety, and participant characteristics rather than retinal risk."

Clinical • Journal • Retrospective data • Review • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 2 Diabetes Mellitus

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study. (PubMed, Cardiovasc Diabetol Endocrinol Rep) - No abstract available

Journal • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Identification and Verification of Immune Metabolism-Related Biomarkers and Immune Infiltration Landscape for Pediatric Opsoclonus Myoclonus Ataxia Syndrome in Neuroblastoma. (PubMed, CNS Neurosci Ther) - "Four immune metabolism-associated diagnostic genes were identified, including TRAF3IP2, RIPK1, KEAP1, and DPP4 for OMAS."

Biomarker • Journal • Ataxia • Movement Disorders • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • KEAP1 • RIPK1 • TRAF3IP2

Dipeptidyl Peptidase 4, a Novel Adipokine, Impairs Retinal Microcirculation in Patients With Type 2 Diabetes Mellitus. (PubMed, Invest Ophthalmol Vis Sci) - "Superoxide scavenger 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), the NADPH oxidase inhibitor apocynin, and the DPP4 inhibitor teneligliptin, prevented the retinal endothelial dysfunction induced by DPP4. Our results indicated that high serum DPP4 concentration may be associated with decreased RBF, probably via the constricted vessel D in men with type 2 diabetes with early-phase DR and further that DPP4 may inhibit endothelium-dependent NO-mediated dilation in the retinal arterioles via producing superoxide from NADPH oxidase."

Journal • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 2 Diabetes Mellitus

SGLT2 Inhibitors Improve Liver Enzyme and Fat Content Patients With MASLD and Type 2 Diabetes: Results of a Meta-Analysis of Randomized Control Trials (ACG 2025) - "In one study, intrahepatic lipid decreased by 5.2% with empagliflozin vs 1.9% with sitagliptin (p = 0.044). Six RCTs (441 patients) were included; 231 received an SGLT2 inhibitor and 210 received a placebo or active comparator (pioglitazone, sitagliptin, teneligliptin). SGLT2 inhibitors led to significant reductions in AST (mean difference −8.0 U/L, 95% CI −14.3 to −1.7, p = 0.014) and ALT (−11.3 U/L, 95% CI −20.6 to −2.0, p = 0.018). All studies reported liver imaging outcomes, with five demonstrating greater reductions in liver fat with SGLT2 therapy."

Retrospective data • Cardiovascular • Diabetes • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

From Diabetes to Dermatology: The Role of Teneligliptin in Bullous Pemphigoid Development. (PubMed, Curr Diabetes Rev) - "It also discusses the clinical implications, such as monitoring for BP in T2DM patients on teneligliptin therapy. Elucidation of this relationship may help in optimizing management strategies by highlighting discontinuation or alternative therapies in the case of a high risk of development of BP."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury. (PubMed, Nephrol Dial Transplant) - "TG and EMPA attenuate tubular cell death and kidney injury in ferroptosis-mediated AKI models, potentially through the reduction of lipid peroxidation. These findings highlight ferroptosis suppression as a potential mechanism underlying their renoprotective effects in AKI prevention."

Journal • Acute Kidney Injury • Inflammation • Nephrology • Renal Disease • GPX4 • MB • NOX4

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. (PubMed, J Endocrinol Invest) - "Imeg and DPP-4i demonstrated favorable antidiabetic effects and good safety. Imeg exhibited comparable glycemic control to that of DPP-4i. Overall, Alog was the most suitable option among the included DPP-4i for T2DM patients with hyperlipidemia. Tene demonstrated significant efficacy in glycemic control, and can be a first-line choice among the included DPP-4i."

Clinical • Journal • Retrospective data • Review • Diabetes • Dyslipidemia • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Handok Inc.

New P1 trial

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed

Trial completion

Teneligliptin alleviates acute kidney injury by exerting anti-ferroptotic effects on renal tubules (ERA 2025) - "Additionally, our previous research suggests that DPP-4 inhibitors may reduce cisplatin-induced AKI in humans [4]. Our study demonstrates that the DPP-4 inhibitor TG provides renoprotective effects against folic acid- and rhabdomyolysis-induced AKI by inhibiting ferroptosis in renal tubular cells. The findings suggest that TG reduces tubular cell death by specifically targeting ferroptotic pathways, as evidenced by its effectiveness in suppressing erastin-induced cell death and the lack of effect from apoptosis and necroptosis inhibitors. These results highlight the potential of TG as a therapeutic option for AKI by modulating ferroptosis-related mechanisms."

Acute Kidney Injury • Colon Cancer • Colorectal Cancer • Nephrology • Oncology • Renal Disease • Solid Tumor • MB

Teneligliptin, a DPP4 Inhibitor Protects Dopaminergic Neurons in PD Models via Inhibiting of Oxidative Stress and Ferroptosis. (PubMed, Eur J Pharmacol) - "Finally, Teneligliptin improved behavioral performance and protected dopaminergic neurons in MPTP-induced PD mouse. Taken together, our findings of Teneligliptin as a promising candidate for the treatment of PD warrant further study."

IO biomarker • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • BAX • BCL2 • GPX4 • KEAP1

Failure Mode Effects Analysis and Design of Experiments to Sensitive and Sustainable Microwave-Aided Spectrofluorophotometric Estimation of Teneligliptin and Method's Chlor-Tox Scale and Blue Applicability Grade Index Assessment. (PubMed, Luminescence) - "The fluorescent product that was derivatized using microwaves was separated and studied using mass spectrometry. After greenness and whiteness profile assessment, researchers discovered that the suggested approach to teneligliptin estimate was eco-friendly, precise, robust, rapid, economical, and easy to apply."

Journal • Hypoglycemia

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Handok Inc.

New P1 trial

Analytical Methods for Estimating Metformin Hydrochloride, Pioglitazone and Teneligliptin in Diabetes Management: a Comprehensive Review. (PubMed, J Chromatogr Sci) - "By offering a comprehensive assessment of the analytical methods used for the estimation of Metformin, Pioglitazone and Teneligliptin for diabetes treatment, this review serves as a valuable resource for researchers, clinicians and pharmaceutical scientists. It aids in selecting the most suitable analytical method for specific applications, contributing to the continuous improvement of diabetes management and treatment."

Journal • Review • Diabetes • Infectious Disease • Metabolic Disorders

HD-MP-106: Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Handok Inc. | Trial completion date: Nov 2024 ➔ Jun 2024 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date

In-vivo Microwave-aided Spectrofluorimetric Characterization of Teneligliptin-loaded Solid Dispersion Adsorbate Using Quality by Design Approach. (PubMed, Anal Biochem) - "The method demonstrated environmental sustainability, robustness, sensitivity, cost-effectiveness, and user-friendliness when evaluated using white analytical chemistry approaches. It provided a sensitive and green alternative to existing hyphenated techniques for nanogram-level teneligliptin detection in pharmacokinetic studies."

Journal • Preclinical

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) (clinicaltrials.gov) - P4 | N=39 | Completed | Sponsor: Handok Inc. | Unknown status ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin (clinicaltrials.gov) - P=N/A | N=2983 | Completed | Sponsor: Handok Inc. | Unknown status ➔ Completed | N=4875 ➔ 2983

Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

TERA 305: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin (clinicaltrials.gov) - P3 | N=214 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed | Trial completion date: May 2025 ➔ Jun 2024

Trial completion • Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pleiotropic effect of teneligliptin versus glimepiride add-on therapy on hs-CRP and cardiorenal parameters in Indian type 2 diabetes patients: An open-labeled randomized controlled trial. (PubMed, Perspect Clin Res) - "The objective of the study was to estimate the pleiotropic effect of teneligliptin on high-sensitivity C-reactive protein (hs-CRP) levels and some cardiorenal parameters in comparison to glimepiride, both as add-on therapy to metformin. Teneligliptin add-on resulted in favorable effects on hs-CRP levels and comparable effects on cardiorenal parameters compared to glimepiride add-on therapy at 12-weeks end.This trial has been prospectively registered in CTRI (Clinical Trials Registry of India). Registration number: CTRI/2021/08/035342."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

TERA 304: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin (clinicaltrials.gov) - P3 | N=235 | Completed | Sponsor: Handok Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Apr 2024 | Trial primary completion date: Nov 2024 ➔ Apr 2024

Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Which antidiabetic drugs do patients of T2DM prefer in India and why? A discrete choice experiment. (PubMed, J Family Med Prim Care) - "Out of the 87 evaluated participant choices, the most preferred drug was Glimepiride (51.7%), followed by Dapagliflozin (22.9%) and Teneligliptin (17.2%). Glimepiride was the most preferred option overall while the effect on weight was the most important attribute for patients in determining their preference. The study highlighted the importance of shared decisions and can guide practitioners in considering patient preferences when prescribing antidiabetic drugs."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies. (PubMed, World J Diabetes) - "Through the use of both in vivo and in vitro models, the study demonstrated that teneligliptin alleviates cardiac hypertrophy, reduces myocardial injury, and mitigates the inflammatory responses associated with DCM. These findings suggest that teneligliptin's cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation, positioning it as a promising therapeutic option for managing DCM in diabetic patients."

Journal • Cardiomyopathy • Cardiovascular • Diabetes • Inflammation • Metabolic Disorders • NLRP3